Unibest
← Back to patent-cliff list

Daridorexant hydrochloride

Tier C — Watch / trade

Daridorexant hydrochloride

Actelion Pharmaceuticals Ltd
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:OX1R, OX2R

Brand:QUVIVIQ, Quviviq

Indications (approved):Insomnia and sleep disorders

Regional status

US
Approved
2022-01-07
EU
Approved
2022-04-29
China
Approved
2025-06-17
Japan
Approved
2024-09-24

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 6 · Total yield /
NEMOR-0011508261-86-6NEMOR-002103336-06-7NEMOR-003673487-36-0NEMOR-0041788104-74-4NEMOR-0051788104-75-5NEMOR-0061788104-76-6NEMOR-0071293284-55-5NEMOR-00854413-93-3NEMOR-009288-35-7Nemorexant—API · Daridorexant hydrochloride
CodeCAS No.Intermediate
NEMOR-0011508261-86-6Available(S)-2-methylpyrrolidine-2-carboxylic acid hydrochloride
NEMOR-002103336-06-7Available(S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid
NEMOR-003673487-36-0Available4-chloro-3-methylbenzene-1,2-diamine
NEMOR-0041788104-74-4Availabletert-butyl (S)-2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate
NEMOR-0051788104-75-5Availabletert-butyl (S)-2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidine-1-carboxylate
NEMOR-0061788104-76-6Available(S)-5-chloro-4-methyl-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride
NEMOR-0071293284-55-5Available5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid
NEMOR-00854413-93-3Available2-iodo-5-methoxybenzoic acid
NEMOR-009288-35-7Available2H-1,2,3-triazole
Nemorexant-(S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Frequently asked questions

What are the approved indications of Daridorexant hydrochloride?

Approved indications include: Insomnia and sleep disorders.

When does the Daridorexant hydrochloride patent expire?

No public expiry year is available for Daridorexant hydrochloride yet; this page updates once verified.

How many synthesis routes are recorded for Daridorexant hydrochloride?

1 synthesis routes are recorded; the shortest is 6 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Daridorexant hydrochloride intermediates?

9 intermediate CAS of Daridorexant hydrochloride are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Daridorexant hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29